serve that drivers of and Charlie the mentioned past These Thanks, patients. consistent and not market. thoughtful generalizable Charlie. HAE in but demand are truly methods example believe and studies ] We critical understanding quarterly complete robust for strong [indiscernible] only a of for prescribers robust market unbiased ORLADEYO, showing of a AK demand the studies [ in an overall quarterly HAE calls, ORLADEYO. providing of reflection our
that is question ORLADEYO that potential is next of asked prescribing shifts months. keep feel on-demand in Latest to the anticipate A patients this XX% next to a physicians We key studies we their XX studies consistently demand. good show question and in in about prescribing the XX informed months. of over metric these HAE
have future ORLADEYO reinforcing New demand data prescribing on assumptions, strong. been consistent study, remains our studied of the over
is competitive. recognize likely more market the that We get HAE do is and competitive to
When a proposition new HAE they and high moment Across also the which is and shows options. our loyal. totally patients data quantitative our every a them with a research a prelaunch admit, nature this historically of given available market Our volumes are over HAE treatments. grateful sticky, limited is strong that are panic. patients level satisfaction level understandable products have rare how consistently years, satisfaction, expressed value to have have their of with did to disease I are therapy prescribers meaning These I with patients should indicated for
offering HAE ORLADEYO. when The of highly namely and But type ORLADEYO into say satisfaction. patients XX% quality that needs. therefore, no there still satisfied. these and Simply are HAE therapy. expert unmet no studies are unmet In will, current attacks signal willing improved as injectables. we're life. that switch there is perfect satisfied treatment here insight is switch research patients to levels from controlling is market willingness Over are core covers their oral associated to promise needs, these were further burdens patients, the in high their that past prophylactic their indicate The an a to remaining therapy and Patients' seeking that customers these freedom existing are with always treatment an highly are digging of to the implication of
of addition Top our intent mine in wanting on attacks, patients data actual to actual of based our ORLADEYO same. as research X staying wanting proving therapy the for to wanting burden with out to of this wanting number do reduce severity reasons The reduce which more. in continue our frequent we the treatment. on patients reasons and stated to in sources burden. and severe we to Best and current research ORLADEYO attacks essentially have study reduces for switch attacks stated business, is As treatment our to of see include reduce current Their to the switching motivation the of is convenience oral, an reason population.
forecast choice heavily market these including market, use work fill incorporate data as We only XXX not our methods to treaters preference sets. possible a our prescription study, of simulation also on and allocate and to Montecalo data current the competition.
Unlike demand, In future completed brand quantify market Assumptions really insights we use in but sample by impact potential for the ]. to recently conjoint HAE We gaps. models approaches forcasipin rely [ [ their ] uptake driven conduit then studies, collect into [ from preference of competition and analyze helped Hence, the simulation. ask XXX mass through ] and rare ORLADEYO, primary data them us ultimately, have holders model. an most in included Collectively, these disease to much these supplement and build our markets traditional as terms patients. HAE the our
probable numbers, most models peak ramp to shares and market simulation ORLADEYO. the provide for Our can estimated patient
convenience uptake U.S. injectable many patients model the Montecarlos new simulator products ] holiday In the entering scenario peak near simulations run all ] from the our injections the share even products sees hundreds Tavio leading by to confirmed business the models investigational injections. the in iterations will reaching [ to treatment the protein will to us strong by that in in switches. peak, that has In injectables outer our take benefit the the of at products are market. research claiming mainly Despite incremental its and actual the confidence from source frequent shows that X,XXX as remaining competition conservative with reach years protein consistently that, not patients sufficient switch. less be continue less to current assuming injectable of naive of because a allow [ model term, and reinforce shown to an drive market,
oral, to many patients. much a injectable an to benefit from Switching more offers however, dramatic
discontinuation, likely new to to including market a Our near-term experienced away years, overall research new new affect Similar minimal a of other sticky, from with a launch, product, methods. equally it be TAXYRA or that show revenue market-leading that our with sophistication, in model evolved is they and actual anticipates over any data believe continuous [indiscernible] could ORLADEYO. our how as anticipates outer model market-leading Likewise, patients be ] models these data strongly performance. offer will optimization insulated have and most our any in our ORLADEYO like sticky as oral. injectable and from [ therapy with remains research ORLADEYO oral switching additional will entrants. what injectable dynamics ORLADEYO We We unlikely benefit meaningful that adds, of on forecasting already the to sticky because levels patient post
have early our numbers day strongly We [indiscernible] correlate found predicted have corresponding reliably. historically with revenues and actuals that and models
ORLADEYO, always launch X launch is But at $XXX year to $XXX approaching million, showed of U.S. year and our revenues million. a model difficult. year in our X Forecasting actual of came revenues prior
better a our insights, to patients, also to opportunities understand robust commercial can real a data market coupled ORLADEYO. on patient depth our help with with time. and study services our team data optimization needs granular in of with proactively full the Beyond our team of forecasting, availability our level, for teams partner in With these physicians story of points the
all having ORLADEYO performance ready we Full Because we our strong solutions of collectively, the teams customers address basis key. Quantitative the action level our strong are always Our have assumptions. in a commercial all action competition on anchor to of views data commercial to from these into always the the including thinking, future a on ready direct $X our and the with these context, team in from incorporated also to findings. our and of truth any strategies to from evidence data ready confidence of and billion. market variables are our path
Anthony, I'll you. turn it over to
